KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells.

Product information

CAS Number: 124875-20-3

Molecular Weight: 598.30

Formula: C21H19Cl4N6Ru

Chemical Name: 1H-indazol-2-ium; bis(1H-indazole); tetrachlororutheniumdiuide

Smiles: Cl[Ru-2](Cl)(Cl)Cl.C1=[NH+]NC2=CC=CC=C21.C1=NNC2=CC=CC=C21.C1=NNC2=CC=CC=C21

InChiKey: JHNYAOQHYLMCJA-UHFFFAOYSA-K

InChi: InChI=1S/3C7H6N2.4ClH.Ru/c3*1-2-4-7-6(3-1)5-8-9-7;;;;;/h3*1-5H,(H,8,9);4*1H;/q;;;;;;;+2/p-3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

KP1019 is internalized by yeast and induces mutations, cell cycle delay, and cell death. KP1019 sensitivity of strains defective in DNA repair is examined, ultimately showing that rad1Δ, rev3Δ, and rad52Δ yeast are hypersensitive to KP1019, suggesting that nucleotide excision repair (NER), translesion synthesis (TLS), and recombination each play a role in drug tolerance. KP1019 inhibits proliferation of ovarian tumor cells, induces DNA damage and apoptosis in colon carcinoma cells. KP1019 causes interstrand cross-links and bulky DNA adducts in mammalian cell lines.

In Vivo:

KP1019 treatment inhibits primary tumour growth in in the model of MCa mammary carcinoma. None of the treatments reduced the development of lung metastatases in this tumour model.

Products are for research use only. Not for human use.